Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegtibatinase in Cystathionine Beta Synthase-Deficient Homocystinuria (COMPOSE)
NCT03406611Phase 2Recruiting
- Sponsor
- Travere Therapeutics
- Start
- Jan 2019
- Primary completion
- Jul 2027
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of pegtibatinase in homocystinuria (HCU) (3 cohorts), sponsored by Travere Therapeutics. Primary endpoints: Incidence of Adverse Events at 32 weeks, Anti-pegtibatinase antibodies at 32 weeks and 4 more. Started Jan 2019; status: recruiting.
02
Drugs
pegtibatinase
03
Conditions
homocystinuria (HCU)
Beyond the preview
Go deeper on NCT03406611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406611.